Extrahepatic 25-Hydroxylation of Vitamin D3 in an Engineered Osteoblast Precursor Cell Line Exploring the Influence on Cellular Proliferation and Matrix Maturation during Bone Development by Mason, Shelley S. et al.
Portland State University
PDXScholar
Biology Faculty Publications and Presentations Biology
1-1-2013
Extrahepatic 25-Hydroxylation of Vitamin D3 in an Engineered
Osteoblast Precursor Cell Line Exploring the Influence on Cellular
Proliferation and Matrix Maturation during Bone Development
Shelley S. Mason
Portland State University
Sean S. Kohles
Portland State University
Shelley R. Winn
Oregon Health & Science University
Randy D. Zelick
Portland State University
Let us know how access to this document benefits you.
Follow this and additional works at: https://pdxscholar.library.pdx.edu/bio_fac
Part of the Cell and Developmental Biology Commons
This Article is brought to you for free and open access. It has been accepted for inclusion in Biology Faculty Publications and Presentations by an
authorized administrator of PDXScholar. For more information, please contact pdxscholar@pdx.edu.
Citation Details
Shelley S. Mason, et al., Extrahepatic 25-Hydroxylation of Vitamin D3 in an Engineered Osteoblast Precursor Cell Line Exploring the
Influence on Cellular Proliferation and Matrix Maturation during Bone Development, ISRN Biomedical Engineering, vol. 2013,
Article ID 956362
Hindawi Publishing Corporation
ISRN Biomedical Engineering
Volume 2013, Article ID 956362, 11 pages
http://dx.doi.org/10.1155/2013/956362
Research Article
Extrahepatic 25-Hydroxylation of Vitamin D
3
in
an Engineered Osteoblast Precursor Cell Line Exploring
the Influence on Cellular Proliferation and Matrix Maturation
during Bone Development
Shelley S. Mason,1 Sean S. Kohles,1 Shelley R. Winn,2 and Randy D. Zelick1
1 Department of Biology, Portland State University, P.O. Box 751, Portland, OR 97207-0751, USA
2Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR 97239, USA
Correspondence should be addressed to Sean S. Kohles; ssk@kohlesbioengineering.com
Received 31 March 2013; Accepted 4 May 2013
Academic Editors: D. K. Han and A. D. Lucas
Copyright © 2013 Shelley S. Mason et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Osteoblastic precursors experience distinct stages during differentiation and bone development, which include proliferation,
extracellular matrix (ECM)maturation, and ECMmineralization. It is well known that vitaminD plays a large role in the regulation
of bonemineralization andhomeostasis via the endocrine system.Theactivation of vitaminD requires two sequential hydroxylation
steps, first in the kidney and then in the liver, in order to carry out its role in calciumhomeostasis. Recent research has demonstrated
that human-derived mesenchymal stem cells (MSCs) and osteoblasts can metabolize the immediate vitamin D precursor 25-
dihydroxyvitamin D
3
(25OHD
3
) to the active steroid 1𝛼,25-dihydroxyvitamin D
3
(1,25OH
2
D
3
) and elicit an osteogenic response.
However, reports of extrahepatic metabolism of vitamin D
3
, the parental vitamin D precursor, have been limited. In this study, we
investigated whether osteoblast precursors have the capacity to convert vitamin D
3
to 1,25OH
2
D
3
and examined the potential of
vitamin D
3
to induce 1,25OH
2
D
3
associated biological activities in osteoblast precursors. It was demonstrated that the engineered
osteoblast precursor derived from human marrow (OPC1) is capable of metabolizing vitamin D
3
to 1,25OH
2
D
3
in a dose-
dependent manner. It was also demonstrated that administration of vitamin D
3
leads to the increase in alkaline phosphatase
(ALP) activity associated with osteoblast ECM maturation and calcium deposits and a decrease in cellular proliferation in both
osteoblast precursor cell lines OPC1 andMC3T3-E1.These findings provide a two-dimensional culture foundation for future three-
dimensional engineered tissue studies using the OPC1 cell line.
1. Introduction
An osteoblastic precursor cell line (OPC1), derived from
human fetal bone tissue, was originally established to provide
a consistent and reproducible culture system for evaluating
bone development, cell/biomaterial interactions, and screen-
ing putative bone differentiating factors [1]. In addition,
OPC1 can be used to study the growth and differentiation
of osteoprogenitors and offers the possibility of examining
events associated with stem cell differentiation to osteoblasts.
Proliferation and differentiation of osteoblasts are regulated
by their respective microenvironment, which encompasses
cells, growth factors and cytokines, and their extracellu-
lar matrix (ECM) [2]. Osteoblasts are a main target for
calcitropic hormones including vitamin D [3, 4]. Several
studies have demonstrated changes in bone development in
response to the steroid hormone vitamin D, especially with
regard to the inhibition of growth during the proliferation
stage and the stimulation of osteogenic differentiation during
thematuration andmineralization stages, albeit the outcomes
appear to be variable and dependent upon the stage of
cellular maturation or differentiation at the time of hormone
responsiveness [5, 6]. Because OPC1 is a stable osteoblast
precursor that has displayed consistent reproducible cultures,
it is an ideal culture system to study the effects of vitamin
D on bone development and elucidate the extraendocrine
metabolism of vitamin D in osteoblasts.
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Vitamin D, also known as calciferol, refers to a collective
group of fat-soluble pluripotent, secosteroid metabolites that
together carry out the known vitamin-D-related functions.
The classic understanding of vitamin D is the essential
role it plays in the regulation and maintenance of cal-
cium and phosphorous homeostasis and bone metabolism.
Elucidating the steps required for the metabolism of vita-
min D precursors, vitamin D
3
(cholecalciferol), and 25-
hydroxyvitamin D
3
(25OHD
3
; calcidiol) to the active hor-
mone 1𝛼,25-dihydroxyvitamin D
3
(1,25OH
2
D
3
; calcitriol)
led to the discovery of regulatory cytochrome P-450 (CYP-
related hydroxylases) involved in the activation and inactiva-
tion of vitamin D and the nuclear vitamin D receptor (VDR)
and its interactions with transcriptional machinery inside
vitamin D target cells [7]. 1,25OH
2
D
3
directly influences
osteoblast binding to the VDR, which consequently elicits
nuclear and extranuclear cellular responses related to the
production and maintenance of the skeleton [3, 4]. Once it
was demonstrated that VDR and vitamin D regulatory CYPs
were present in multiple tissues and cells not involved in the
classic endocrine actions of vitamin D, it was acknowledged
that its functions extended far beyond mineral homeostasis
and bone metabolism. It is now recognized that vitamin D
is associated with the regulation of many cellular processes
including proliferation, differentiation, and apoptosis inmul-
tiple tissues in a paracrine/autocrine manner [7–9].
Vitamin D, in the form of vitamin D
3
, is endogenously
made from cholesterol in the skin when it is exposed to ultra-
violet light (UVB). Alternatively, vitamin D can be acquired
by diet in either the vitamin D
3
(derived from animals)
or vitamin D
2
(derived from plants) form. There are many
metabolites or isomers of vitamin D. The active metabolite,
1,25OH
2
D
3
, and the immediate metabolic precursor to the
active metabolite, 25OHD
3
, are among the most studied.
Vitamin D
3
, the metabolic precursor to 25OHD
3
, itself is
biologically inert, or inactive, in that it does not directly
increase the active transport of calcium or mediate any
of the other vitamin-D-related activities in physiological
concentrations unless it is metabolized to a more polar
compound [10]. In the classic endocrine metabolic pathway
of vitamin D, both endogenous vitamin D
3
and dietary
vitamin D
3
undergo sequential steps of activation by being
hydroxylated in the liver to 25OHD
3
by CYP-related 25-
hydroxylase (CYP27A1) and then to 1,25OH
2
D
3
by 25-
hydroxyvitamin D
3
-1𝛼-hydroxylase (CYP27B1) in the kid-
neys [7, 11, 12]. While early data suggested that the liver is the
only significant site of 25-hydroxylation in vivo, there have
been occasional reports of extrahepatic 25-hydroxylation
of vitamin D
3
[7, 13]. Recently, extrarenal metabolism of
25OHD
3
to 1,25OH
2
D
3
has been demonstrated definitively
[9, 14]. In vitro, many nonrenal cells, including mesenchymal
stem cells (MSCs), bone, cartilage, keratinocytes, placenta,
prostate, macrophages, lymphocytes, dendritic cells, and
several cancer cell lines, can convert 25OHD
3
to 1,25OH
2
D
3
[14]. Several of these cell types have been shown to express
both CYP27 hydroxylase enzymes required for the activation
of vitamin D
3
, which may explain the occasional reports of
extrahepatic 25-hydroxylation of vitamin D
3
[7, 13, 15].
The molecular effects of vitamin D are mediated through
the intranuclear receptor VDR, which acts as a ligand-
activated transcription factor for target genes when bound to
1,25OH
2
D
3
[16]. 1,25OH
2
D
3
has a high affinity for VDR and
upon binding forms a heterodimer with the retinoid X recep-
tor, which allows it to bind to the response/receptor element
(VDRE) in the promoter regions of target genes [8, 17, 18].
The genes include those associatedwith calciumhomeostasis,
immune response and maintenance of immune cells, cellular
growth, differentiation, cell cycle arrest, apoptosis, and
the enzymes required for their own metabolism [17–20].
1,25OH
2
D
3
influences many aspects of bone cell biology and
has been implicated in the regulation of both osteoblastic and
osteoclastic activity affecting both resorptive and synthetic
phases of bone remodeling [21]. In addition, 1,25OH
2
D
3
has
been demonstrated to regulate osteoblast and chondrocyte
gene transcription, proliferation, differentiation, and
mineralization of ECM [20, 21]. More than 30 tissues are
known to have nuclear receptors for 1,25OH
2
D
3
, and it is
known to regulate the function of more than 60 genes [11, 13,
17, 22]. Because of its role in proliferation and differentiation,
it has been hypothesized that the local production of
1,25OH
2
D
3
in extrarenal tissues serves to regulate growth
and differentiation in an autocrine/paracrine fashion
[21, 23].
Despite the increase in research over the last few decades,
further investigation on vitamin D metabolism and regula-
tion needs to be carried out in order to elucidate extraen-
docrine metabolism and local production of 1,25OH
2
D
3
.
While there has been an increase in the reports of extrarenal
1,25OH
2
D
3
synthesis and occasional reports of extrahepatic
25-hydroxylation of vitamin D
3
, to our knowledge, there is
no detailed analysis of extrahepatic vitamin D
3
metabolism
in osteoblast precursors. Furthermore, paracrine/autocrine
regulation and gene expression that result in local changes
in proliferation and differentiation need to be further inves-
tigated to understand the potential application of vitamin
D for regenerative medicine. In this study, we investigated
whether osteoblast precursors have the capacity to convert
the parental vitamin D precursor, vitamin D
3
, to 1,25OH
2
D
3
and examined the potential of vitamin D
3
to induce
1,25OH
2
D
3
associated biological activities in osteoblast
precursors.
2. Materials and Methods
2.1. OPC1 and MC3T3-E1 Cell Cultures. Vitamin D
3
(chole-
calciferol) and 1,25OH
2
D
3
(calcitriol) were purchased and
maintained in 10mM and 10𝜇M stock solutions in ethanol,
respectively (Sigma-Aldrich, St. Louis, MO). All other
reagents and chemicalswere purchased from the same vendor
unless otherwise indicated. Original OPC1 and MC3T3-E1
cell lines were cultured on site (Department of Molecular
& Medical Genetics, Oregon Health & Science University,
Portland, OR).
Cells were cultured at populations of 2.5 × 105 in 75 cm2
tissue culture flasks in alpha modified essential medium (𝛼-
MEM) with 5% fetal bovine serum (FBS). Once confluent,
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OPCs were plated in 12-well plates after trypsin-ethylene-
diaminetetraacetic acid (EDTA) enzymatic removal and
counted with 0.4% trypan blue (1 : 1) on a hemacytome-
ter. Cultures were then prepared in duplicate at a seed-
ing density of 2.5 × 104 cells/well in the initial bone
medium (designated as BM−) with 200mM L-Glutamine
and antibiotics for at least 4 hours before creating exper-
imental groups based on additive culture medium. Six
types of medium-based groups were prepared. BM− pro-
vided a negative control (Group 1) and the additional
groups included BM− supplemented with 1 𝜇M vitamin
D
3
(Group 2); BM− supplemented with 10 nM 1,25OH
2
D
3
(Group 3); BM− supplemented with osteogenic factors
(BM+) comprised of 10mM 𝛽-glycerophosphate, 10 nM
dexamethasone, and 50 𝜇g/mL of ascorbic acid phosphate
(Wako Chemical, Osaka, Japan) represented the positive
control (Group 4); BM+ supplemented with 1𝜇Mvitamin D
3
(Group 5); and BM+ supplemented with 10 nM 1,25OH
2
D
3
(Group 6). Fresh medium was added every 1 to 3 days.
2.2. Cell Proliferation. OPC1 and MC3T3-E1 cell lines were
evaluated for growth kinetics while maintained in the pres-
ence of vitamin D metabolites, vitamin D
3
and 1,25OH
2
D
3
,
with (BM+) or without (BM−) osteogenic factors, at the
indicated experimental group concentrations. Each sample
set was cultured for at least two weeks in duplicate or
quadruplicate. Every 2 to 5 days, following the addition of
experimentalmedia and at the end of each incubation period,
cell proliferation was measured using crystal violet solution
(CVS, Sigma-Aldrich). Cultures were rinsed with Dulbecco’s
phosphate buffered saline (DPBS) and fixed for 15 minutes in
95% ethanol. The fixed cells were rinsed several times with
distilled water and stained for 10 minutes with CVS.The CVS
was then extracted from the cells after a 4 h incubation in 1%
Triton X-100 at room temperature. The samples were then
stored at −80∘C until the end of each experimental period.
Triton extracts were measured at 570 nm on a microplate
reader (Cary 50, Varian Australia Pty. Ltd.). Absorbance
values were converted into cell numbers extrapolated from
standard growth curves.
2.3. Alkaline Phosphatase. As described above, OPC1 and
MC3T3-E1were treatedwith both vitaminD
3
and 1,25OH
2
D
3
in the BM− and BM+ experimental groups. Alkaline phos-
phatase (ALP) activity was measured every 3 to 4 days. At
the end of the incubation, the cell layers were washed three
times with DPBS, scraped off of the plates with 500𝜇L DPBS,
and stored at−80∘Cuntil the end of each experimental period
(2 to 3 weeks). Each sample was subjected to three freeze-
thaw cycles in order to lyse the cells. ALP activity in the cell
lysates was measured using 𝜌-nitrophenyl phosphate liquid
substrate system at 37∘C for 30 minutes. Protein content was
measured using a microvolume spectrophotometer system
(Epoch, Biotek, Winooski, VT).
2.4. Matrix Mineralization. A histochemical analysis of min-
eralization was evaluated utilizing an Alizarin Red S (ARS)
assay. ARS staining is used to evaluate calcium-rich deposits
by cells in culture and is considered a functional in vitro
endpoint reflecting advanced cell differentiation [24]. In brief,
after 10 to 15 days in culture, cells were fixed in 95% ethanol
for 15minutes then rinsed thoroughlywith distilledwater and
stained with 40mM of ARS (pH = 4.1) at room temperature
for 20min with gentle shaking.The cell layers were efficiently
rinsed with distilled water and observed both grossly and
microscopically. For semi-quantification, ARS was extracted
from the cells after incubating for one hour at room temper-
ature in 10% volume to volume (v/v) acetic acid with gentle
shaking, and then the residual dye was further extracted by
scraping the cells and heating at 85∘C on a heating block with
a layer of mineral oil to prevent evaporation. The samples
were neutralized with 10% (v/v) ammonium hydroxide,
and the extracts were read at a resolution of 405 nm on the
microplate reader. The samples were compared to a serially
diluted ARS standard. The resulting data were normalized
using cell numbers extrapolated from the CVS proliferation
data.
2.5. Vitamin 𝐷
3
Metabolism. Vitamin D metabolism by
OPC1 was performed in a dose-dependent manner over
a 24-hour period. The conversion of 1,25OH
2
D
3
from
vitamin D was quantitatively measured using an enzyme-
linked immunosorbent assay (ELISA) kit (Human 1,25-
dihydroxyvitamin D
3
DVD/DHVD3, NB-E10878, Novatein
Biosciences, Cambridge, MA). OPC1 was plated in 6-well
plates at a seeding density of 105 cells/well. Upon confluency,
experimental media were added in duplicates when creating
experimental groups slightly modified from those described
in Section 2.1: base medium (BM−) provided a negative con-
trol (Group 1); BM− supplemented with 10 nM 1m25OH
2
D
3
as a positive control (Group 2); BM− supplemented with
10 nM vitamin D
3
(Group 3); BM− supplemented with
1 𝜇M vitamin D
3
(Group 4); and BM− supplemented with
10 𝜇M vitamin D
3
(Group 5). The assay was carried out via
manufacturer’s protocol.
2.6. Statistical Analysis and Mathematical Modeling. Statis-
tical analyses were carried out using commercial software
(Prism, Irvine, CA; JMP Pro v10, SAS Concepts, Inc., Cary,
NC; Excel, Microsoft, Redmond, WA). Data were expressed
as means ± standard error of the mean (SEM) of samples
characterized in three two-week sample sets plated in dupli-
cate or quadruplicate and assayed in duplicate (𝑛 = 12 or
𝑛 = 24, resp.). One-way and two-way analysis of variance
(ANOVA) and linear regression statistically assessed the
culture treatments through time and between experimental
groups, with asterisks of ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 <
0.001 indicating varying levels of statistical significance.
Bonferonni posttest (direct comparisons with controls) and
Dunnett’s test (pairwise comparisons) were applied where
appropriate.
Through the ELISA assay protocol for examining the
dose-response of the metabolized form of vitamin D, the
input dosage levels (𝑥-values) were controlled and distributed
at logarithmic concentration levels (in units of ng/mL). A
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Figure 1: Alkaline phosphatase activity (ALP) of osteoblast pre-
cursor OPC1 and MC3T3-E1 after 10 days in culture after being
treated with or without vitamin D
3
(BM− control). After 10 days
there was not a significant effect (𝑃 = 0.2166) on ALP activity
between treatment with either 1𝜇M or 10𝜇M vitamin D
3
; however,
there was an overall statistically significant increase (𝑃 = 0.0026) in
ALP activity between vitamin D
3
treated cultures and controls.
log-base-10 model was applied to the resulting response data
(𝑦-values in pmol/mg protein) in the form:
𝑦 = 𝑚 Log10𝑥. (1)
Here, the coefficient (𝑚) was identified as a fitting parameter
optimizing the model’s representation of the collected data.
Themodel was applied to themetabolized vitaminD concen-
tration data. Least squares estimates were constructed for the
log-coefficient via a quasi-Newton convergence method with
commercially available software (Solver, Frontline Systems,
Inc., Incline Village, NV; Excel, Microsoft, Redmond, WA).
The model fit was again determined by minimizing the
root mean square error (RMSE) between the actual and
response concentrations. The correlation coefficient (𝑅2)
further assayed the strength of the modeled relationship.
2.7. Microscopic Imaging. Microscopic images were taken
using an advanced transmitted light inverted microscope
(EVOS-XL) and accompanying software (EVOS3), both com-
mercially available (Advanced Microscopy Group, Bothell,
WA). Images were processed using an open source, image-
processing package (Fiji, ImageJ v1.47d, National Institutes
of Health, Bethesda, MD). To maintain consistency, each
image was processed in the same manner including main-
taining consistent light intensities during optical density
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Inﬂuence of vitamin D3 concentration on ECM 
BM− control 1𝜇M vitaD3 10𝜇M vitaD3
Figure 2: Semiquantification of matrix mineralization was con-
ducted by taking the optical density (resolution = 450 nm) of the
ARS extracted from each treatment group. Vitamin D
3
at both 1𝜇M
and 10𝜇M dosages did not have a statistically significant effect on
the ECM mineralization of OPC1 (𝑃 = 0.2881) or MC3T3-E1 (𝑃 =
0.1101) after 10 days, compared to the control group.
measurements.The operations included the background sub-
traction command, mean filter, and local contrast (CLAHE
commands: block size 100, bin 256, and maximum slope
2.50, resp.).
3. Results
3.1. ALP Activity and Early Matrix Mineralization. As
described, in order to determine the optimal dose of vitamin
D
3
, OPC1 and MC3T3-E1 cells were cultured at a seeding
density of 5.0 × 104 in quadruplicates with 1 or 10 𝜇Mvitamin
D
3
in standard bone medium (BM−) or in a BM− vehicle
control containing the equivalent amount of ethanol for 10
days in 12-well plates. After 10 days, twowells fromeach group
were prepared for ALP assay, and two wells were stained
with ARS to assess ECM calcium deposition. OPC1 treated
with vitamin D
3
at either concentration had a statistically
significant (𝑃 < 0.001) increase in ALP activity compared
to that of the control (Figure 1). There was no statistically
significant difference (𝑃 > 0.05) between experimental
groups containing either 1 𝜇M or 10 𝜇M vitamin D
3
. There
was also no statistically significant difference (𝑃 = 0.2388) in
ALP activity between MC3T3-E1 treated with either 1𝜇M or
10 𝜇M vitamin D
3
compared to that of the control. However,
in the wells treated with 10𝜇M vitamin D
3
, we observed a
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Figure 3: Absolute proliferation of OPC1 cells maintained in six
types of tissue culture medium over three two-week periods (𝑛 =
24). At day 5, the OPC1 cell counts in the wells containing vitamin D
metabolites ± osteogenic factors (BM+) were statistically lower than
the negative control (BM−). OPC1 treatedwith BM+and 1,25OH
2
D
3
experienced the largest statistically (𝑃 < 0.001) antiproliferative
effect. By day 10, OPC1 treated with BM+ and active 1,25OH
2
D
3
remained around 50% of the BM− cellular confluency. The effect
of vitamin D
3
was similar to 1,25OH
2
D
3
in both groups of media.
Means ± SEM are shown with linear trendlines in the same color
scheme for each experimental group.
variable effect on ALP activity and an adverse effect on cell
viability, which was observedmicroscopically throughout the
experiment (Figure 2).There was not a significant increase in
calcium deposition in ECM in either cell lines compared to
the ethanol vehicle control (𝑃 > 0.05).
3.2. Influence of Vitamin 𝐷
3
and 1,25OH
2
D
3
on Osteoprecursors
3.2.1. Antiproliferative Effects. As described, OPC1 and
MC3T3-E1 were cultured for two weeks with either 10𝜇M
vitamin D
3
or 10 nM 1,25OH
2
D
3
with (BM+) or without
osteogenic factors (BM−) and then compared to BM− and
BM+ ethanol vehicle controls. Proliferation kinetics were
quantitatively compared after conducting a CVS assay as
a function of time. The CVS proliferation assay indicated
a statistically significant inhibition of cell proliferation in
OPC1 treated with 10 𝜇M vitamin D
3
in the same manner
as cells treated with 10 nM 1,25OH
2
D
3
, compared to that of
the BM− and BM+ ethanol controls (shown as absolute cell
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Figure 4: Absolute proliferation of MC3T3-E1 cells maintained in
six types of tissue culturemedium in duplicates over three two-week
periods and assayed in duplicates (𝑛 = 12). Two types of media
were used, one with osteogenic factors (BM+) and one without
(BM−). At day 5, the MC3T3-E1 cell counts in the wells containing
vitamin D metabolites ± osteogenic factor were statistically lower
than the negative control (BM−). At day 10, the OPC1 cell counts
in the wells containing vitamin D metabolites ± osteogenic factors
(BM+) were also statistically lower (𝑃 < 0.001) then than the
negative control (BM−) and remained at around 50% of the BM−
cellular confluency. MC3T3-E1 cells treated with BM+ and vitamin
D
3
were indistinguishable from 1,25OH
2
D
3
in that both experienced
the largest statistically (𝑃 < 0.001) antiproliferative effect. Means ±
SEM are shown with linear trendlines in the same color scheme for
each experimental group.
populations in Figure 3). Groups containing BM+ overall,
had lower proliferation rates than with BM− groups; however
groups treated with BM+ containing either vitamin D
3
or
1,25OH
2
D
3
were significantly lower than the BM− groups.
Growth kinetics of MC3T3-E1 cultured with BM+ and 10 𝜇M
vitamin D
3
were indistinguishable from cells cultured in
BM+ containing 10 nM 1,25OH
2
D
3
(shown as absolute cell
populations in Figure 4). Results were consistent for both
absolute and percentage based cell population analyses.
3.2.2. ECM Maturation. Increased ALP activity was directly
associated with osteoblast function and matrix maturation
during the active stages of bone development (Figure 5).
Treatment of OPC1 cells with standard bone medium (BM−)
and both vitaminD
3
and 1,25OH
2
D
3
stimulated a 2- to 3-fold
increase inALP activity after twoweeks relative to the parallel
6 ISRN Biomedical Engineering
Table 1: ALP activity of OPC1 and of MC3T3-E1 cells maintained in six types of tissue culture medium experimental groups over three two-
week periods (n= 12). After twoweeks, both theOPC1 andMC3T3-E1 ALP activity values of 1,25OH2D3 and osteogenic factors (BM+) treated
cells were statistically greater than the negative control (BM−). ALP activity ofOPC1 treatedwith vitaminD3 andBM+was significantly higher
than BM− but not higher than the BM+ control containing ethanol vehicle. All groups containing BM+ had a statistically greater ALP activity
compared to the control in the MC3T3-E1 cell line. Also, the MC3T3-E1 response to vitamin D3 treatment was indistinguishable from the
response to 1,25OH2D3 treatment.
Maximum ALP activity (mean % [SEM])
Cell type Experimental group Culture time (days)
2 5 9/10 14/15
OPC1
BM− control 6.95 [4.29] 12.49 [2.53] 15.73 [4.64] 21.39 [6.16]
BM− vitaD3 7.59 [4.60] 21.27 [8.72] 22.45 [6.60] 34.87 [11.29]
BM− 1,25OH2D3 6.15 [2.48] 11.21 [0.42] 15.63 [2.48] 31.90 [7.05]
BM+ control 8.99 [4.87] 19.20 [5.92] 40.23 [4.71] 69.11 [12.02]
BM+ vitaD3 9.63 [5.42] 11.11 [2.86] 21.48 [10.74] 62.90 [15.56]
BM+ 1,25OH2D3 5.07 [1.04] 18.77 [7.70] 54.10 [22.78] 99.81 [0.14]
MC3T3-E1
BM− control 1.41 [0.79] 4.44 [1.37] 5.31 [1.39] 26.21 [5.04]
BM− vitaD3 2.72 [0.53] 7.83 [3.13] 13.46 [3.81] 32.44 [10.10]
BM− 1,25OH2D3 2.82 [1.50] 9.18 [3.80] 13.79 [6.00] 40.29 [14.42]
BM+ control 4.13 [2.33] 11.94 [7.78] 22.67 [6.74] 81.17 [9.74]
BM+ vitaD3 2.25 [0.90] 15.76 [8.26] 24.95 [7.42] 88.24 [6.12]
BM+ 1,25OH2D3 2.55 [1.37] 13.19 [5.03] 42.76 [13.35] 84.03 [8.71]
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Figure 5: ALP activity of OPC1 and MC3T3-E1 cells maintained
in six types of tissue culture medium aggregated over three two-
week periods (𝑛 = 12). After two weeks, the OPC1 ALP activity
of 1,25OH
2
D
3
and osteogenic factors (BM+) treated cells were
statistically greater when compared to the negative control (BM−).
ALP activity of OPC1 treated with vitamin D
3
and BM+ was
significantly higher than BM− but not higher than the BM+ control
containing ethanol vehicle. All cellular groups containing BM+ had
a significantly higher ALP activity compared to the control within
the MC3T3-E1 cell line. MC3T3-E1 response to vitamin D
3
was
indistinguishable from the response to 1,25OH
2
D
3
.
control culture, while treatment with osteogenic medium
(BM+) containing 1,25OH
2
D
3
stimulated a 5-fold increase
in ALP activity in comparison to BM− and a 20% increase
in comparison with the BM+ control (Table 1). However,
treatment of MC3T3-E1 cells with BM− containing either
vitamin D
3
or 1,25OH
2
D
3
showed a slight increase in ALP
activity, while BM+ containing either vitamin D metabolite
was increased by 20% when compared to the parallel control
and a 70 to 80% increase when compared to the BM− control
(Table 1).
3.2.3. ECM Mineralization. The ability to mineralize the
ECMduring bone development provides the functional niche
of osteoblasts in vitro and in vivo [25]. OPC1 groups cultured
in BM+ containing vitamin D
3
(𝑛 = 8) or 1,25OH
2
D
3
(𝑛 = 8)
had a statistically larger amount of ECM calcium compared
to the BM− (𝑃 < 0.001) and BM+ (𝑃 = 0.027) ethanol
vehicle controls based on ARS measurements (Figure 6).
The optical density of the OPC1 cell culture (measured in
normalized ARS) increased by 100% relative to the negative
control (BM−) and by about 10% compared to the BM+
parallel control (Figure 8). OPC1 cells treated with BM+
and vitamin D
3
(39.68 ng/mg/106 cells ± 0.75, 𝑛 = 8)
were indistinguishable from cells cultured with BM+ and
1,25OH
2
D
3
(39.69 mean ± 1.00, 𝑛 = 8) (𝑃 < 0.05). MC3T3-
E1 groups cultured in BM+ containing vitamin D
3
(𝑛 = 8)
or 1,25OH
2
D
3
(𝑛 = 8) had a statistical greater amount of
ECM calcium compared with treatment groups with only
BM− (𝑃 < 0.001). Meanwhile, cultures with BM+ and
1,25OH
2
D
3
had a statistically greater amount of ECMcalcium
compared with the BM+ parallel control (𝑃 = 0.0055)
(Figures 7 and 8).
ISRN Biomedical Engineering 7
500𝜇m
(a)
500𝜇m
(b)
500𝜇m
(c)
500𝜇m
(d)
500𝜇m
(e)
500𝜇m
(f)
Figure 6: Osteoblast precursor cell lines OPC1 stained with ARS after two weeks in experimental conditions. Images of OPC1 cells without
either osteogenic factors (BM−) or vitamin D (ethanol control) (a), BM− with 1 𝜇M vitamin D
3
(b), and BM− with 10𝜇M vitamin D
3
(c)
consistently did not absorb a statistically perceptible amount ofARS compared to groups containing osteogenic factors (BM+) (d–f).However,
cells cultured with BM+ and 1𝜇M vitamin D
3
(e) and BM+ with 10 𝜇M vitamin D
3
(f) had a statistically significant (𝑃 < 0.05) amount of
calcium associated with ECMmineralization compared to the BM+ control (d). Magnification = ×10, scale = 500𝜇m.
3.3. Endogenous 1,25OH
2
D
3
Synthesis by OPC1. OPC1 cul-
tures were tested for their ability to synthesize 1,25OH
2
D
3
from the parental precursor vitamin D
3
. For this dose-
response assay, cells were cultured at high density in order
to maximize the concentration of secreted 1,25OH
2
D
3
. Low
serum conditions were also used and compared with a
serum control to account for any potential influence of
vitamin D metabolites present in the serum. OPC1 cultured
in the presence of vitamin D
3
produced a detectable level of
1,25OH
2
D
3
that elevated with increasing concentration. The
synthesis of 1,25OH
2
D
3
inOPC1 correlated logarithmically to
the dosage of vitamin D
3
when applying the log model of (1)
(𝑅2 = 0.9898, 𝑃 = 0.0051, and𝑚 = 7.23 ng/mL) (Figure 9).
4. Discussion
We investigated whether osteoblast precursors have the
capacity to convert vitamin D
3
to 1,25OH
2
D
3
and examined
the potential of vitamin D
3
to induce 1,25OH
2
D
3
associated
biological activities in osteoblast precursors. The active form
of vitamin D, 1,25OH
2
D
3
, is generated from the parental
precursor of vitamin D
3
which requires two sequential
hydroxylation steps catalyzed by mitochondrial cytochrome
P450 enzymes, CYP27A1, and CYP27B1, respectively [26].
We found that OPC1 is capable of synthesizing 1,25OH
2
D
3
by administering vitamin D
3
in a dose-dependent manner
and that the influences of vitaminD
3
on antiproliferation and
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Figure 7: Osteoblast precursor cell line MC3T3-E1 stained with ARS after two weeks within the experimental treatment groups. MC3T3-
E1 cells without either osteogenic factors (BM−) or vitamin D (ethanol control) (a), BM− with 1 𝜇M vitamin D
3
(b), and BM− with 10 nM
1,25OH
2
D
3
(c) consistently did not absorb a significant amount of ARS compared to groups containing osteogenic factors (BM+) (d–f). Cells
cultured with vitamin D
3
and BM+ (e) were statistically significant compared to the negative control (a) but were not comparable with the
parallel control (d). However, cells cultured with BM+ and 10 nM 1,25OH
2
D
3
(f) had a statistically significant (𝑃 = 0.0055) amount of calcium
associated with ECMmineralization compared to the BM+ control (d). Magnification = ×10, scale = 500𝜇m.
osteoblast differentiation were very similar to 1,25OH
2
D
3
.
It was also found that vitamin D
3
induced ALP activity
and calcium deposition associated with ECM maturation
and mineralization during early bone development in a
manner that was indistinguishable from groups treated with
1,25OH
2
D
3
. These findings have important implications for
bone and vitamin D research because they provide further
evidence that local production of active 1,25OH
2
D
3
can occur
in osteoprecursors and that local metabolism of vitamin D
3
can influence bone development.
Several osteoblast culture systems have demonstrated
that cells undergo a temporal developmental sequence that
starts with a proliferation phase and results in fully mature
osteocyte-like cells embedded in mineralized ECM [5, 27].
There are three stages of in vitro bone development that
have been characterized bymorphology and gene expression.
These are (1) a proliferation and ECM biosynthesis stage,
(2) an ECM development and maturation stage noted by
an increase in ALP activity, and (3) a final stage of ECM
mineralization in which hydroxyapatite is organized and
deposited [5, 6, 27]. In the first stage, following initial cell
seeding, the cells actively proliferate for the first 10 to 12
days of culture, and several genes associated with ECM
formation, including type I collagen and osteopontin, are
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Figure 8: Semi-quantification of matrix mineralization of cultured
experimental groups shown in Figures 6 and 7 after two weeks of
treatment. OPC1 treated with vitaminD
3
or 1,25OH
2
D
3
in BM+ had
a statistically significant (𝑃 < 0.05) amount of calcium deposition
in comparison to both BM− and BM+ controls. MC3T3-E1 cells
cultured with 1,25OH
2
D
3
in BM+ had a statistically significant (𝑃 =
0.0055) amount of calcium deposition in comparison with both
BM− and BM+ controls.
actively expressed and then gradually decline as proliferation
rate decreases and ECM maturation begins. We report that
both vitamin D
3
and 1,25OH
2
D
3
had similar effects on two
osteoprecursor cell lines, which influenced the proliferation
stage of bone development by significantly hampering the
growth rate.
Immediately following the decrease in proliferation, ALP
activity is greatly increased. This postproliferative period
occurs between days 12 and 18, and it is during this time that
the ECM matures and becomes competent for mineraliza-
tion [5, 6]. Here, ALP activity of untreated osteoprecursors
steadily increased, while the groups containing osteogenic
factors (BM+) and either vitaminD
3
or 1,25OH
2
D
3
increased
more than 10-fold over a two-week period of time. While
the measurement of increased ALP expression is used as an
osteogenic marker as an indication of osteoblast phenotype,
its function still remains unclear. It has been postulated
to increase concentration of inorganic phosphate, a con-
cept known as the “booster hypothesis” [28]. During the
third stage of bone development, ALP expression decreases,
and other genes associated with bone mineralization are
expressed at maximal level [6, 27, 28]. These bone cell syn-
thesized proteins include osteopontin (OP) and osteocalcin
(OC) and are known to interact with themineralized ECM in
vivo [6]. OP is expressed in both the proliferation and min-
eralization periods and downregulated postproliferatively
during matrix maturation; however, during proliferation,
OP expression reaches only about 25% of its maximal level
which peaks between days 16 and 20 during mineralization.
In contrast, the calcium binding protein OC, which binds
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Figure 9: Endogenous production of 1,25OH
2
D
3
by OPC1 in
response to incubation with vitamin D
3
. A 1,25OH
2
D
3
/VDR ELISA
was performed to analyze themetabolismof precursor vitaminD
3
to
the hormonally active form. The dose of vitamin D
3
was controlled
and administered at logarithmic concentration levels. A log-base-10
model was applied to the resulting response data.
to hydroxyapetite, is expressed only postproliferatively with
the onset of nodule formation and is expressed maximally
with ECM mineralization in vivo and in vitro [6]. We saw
minimal calciummineralization after two weeks in untreated
cell cultures as well as calcium mineralization of the ECM
in cultures that were treated with osteogenic factors (BM+)
and vitamin D
3
or 1,25OH
2
D
3
. However, further studies
need to be carried out for a longer duration to see maximal
levels of ECM mineralization that are associated with bone
development.
The osteoprecursor cultures observed in the present
work were nonconfluent cultures with actively dividing
cells. Because vitamin D has an antiproliferative effect, it is
important to look at its influence on osteoblast precursors
after proliferation begins to decrease in order to get a better
understanding of how vitamin D affects a confluent cell
population. Both OPC1 and MC3T3-E1 cultures treated with
vitamin D
3
or 1,25OH
2
D
3
did not reach confluency during
the 15 day culture period, while the control groups reached
confluency at around 10 to 12 days after an initial seeding den-
sity of about 6,500 cells/cm2. Confluent osteogenic cultures,
including MC3T3-E1 cells and human bone marrow derived
stromal cells (BMSCs), follow a two-stage developmental
process including a 1- to 2-week initiation phase during
which cells slowly proliferate, express ALP activity and other
bone specific genes, and produce and assemble a collagen
matrix and a second maturation phase occurring in weeks
2 to 3 in which ECM mineralization is observed [24].
Mineralization has been demonstrated in BMSC cultures that
achieve a minimal ALP activity (∼0.25 nmol/min/𝜇g protein
or 1.2 nmol/min/10,000 cells) at some point during the 2
to 3 week culture period, albeit some BMSC cultures can
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produce high levels of ALP in vitrowithout ever mineralizing
[24]. Treatments applied here tended to speed up maturation
at the expense of proliferation; hence, confluency would be
achieved more slowly (or not at all, in this case) relative to
control cultures. The effects of vitamin D on ALP activity
and mineralization of ECM on confluent OPC1 cultures are
currently under way.
One limitation here is that because supraphysiological
doses (≥10−7M) of vitamin D
3
(10 𝜇M) and 1,25OH
2
D
3
(10 nM)were used to achieve amaximal response, it is unclear
how relevant our findings are to the action of lower vitamin
D
3
levels within the physiologic range. In vivo, doses of
vitamin D
3
as low as 10 𝜇g (400 IU) have been shown to
stimulate bone mineral augmentation in adolescents [29],
and the administration of physiological doses of 1,25OH
2
D
3
has been shown to cure vitamin-D-dependency rickets I
[30]. Our findings indicated that, for an in vitro system,
supraphysiological doses had a positive effect on bone matu-
ration and mineralization and a negative response in cellular
proliferation.
Another limitation is that an insufficient amount of RNA
was obtained from the groups containing vitamin D
3
and
1,25OH
2
D
3
to permit simultaneous analysis by qRT-PCR of
multiple primers. This was due to the fact that both vitamin
D
3
and 1,25OH
2
D
3
inhibited proliferation, which lead to a
much smaller population size in comparison to the controls.
Advancements in the design of biomedical engineer-
ing technologies, especially those supporting regenerative
medicine through cell and tissue engineering, include the
use of precursor cell lines which can consistently be manip-
ulated to develop neotissue. The OPC1 cell line investigated
here maintained consistent proliferation, ECM synthesis,
and boney maturation, albeit during an abbreviated two-
dimensional study. Future investigations will recreate the
culture scenarios in a three-dimensional, cell-biomaterial
construct with concomitant mechanical stimulation through
the application of a novel bioreactor [31]. This approach will
establish a surrogate living tissue model for pharmacokinetic
assessment of the dose-response relationship building off of
the foundation described here.
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